Table 1—

Studies included in the integrated analysis

Study (ref. no.)Number of randomized and treated patientsStudy durationPrestudy treatmentStudy treatmentAdditional antidiabetic treatment
3002 (8,14)57052 weeks*OAD and once-daily insulin or OAD aloneOnce daily at bedtime: insulin glargine or NPH insulinOAD(s)
3006 (12,15)51828 weeksInsulin for >3 months (no OAD)Insulin glargine once daily at bedtime or NPH once or twice dailyRegular human insulin
4001 (16)46028 weeksOAD for >6 monthsOnce daily at bedtime: insulin glargine or NPH insulinOAD (glimepiride)
4002 (13)75624 weeksOAD aloneOnce daily at bedtime: insulin glargine or NPH insulinOAD(s)
  • *

    * The 20-week data used for the original study were included in this analysis.

  • In this study, insulin glargine was given once daily at breakfast or bedtime. Only those receiving insulin glargine at bedtime are included in this analysis. OAD, oral antidiabetic drug.